C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration
Age-related macular degeneration (AMD), a retinal degenerative disease, is the leading cause of central vision loss among the elderly population in developed countries and an increasing global burden. The major risk is aging, compounded by other environmental factors and association with genetic var...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2018.00808/full |
| _version_ | 1811315410244468736 |
|---|---|
| author | Blanca Molins Sara Romero-Vázquez Pablo Fuentes-Prior Pablo Fuentes-Prior Alfredo Adan Andrew D. Dick Andrew D. Dick Andrew D. Dick |
| author_facet | Blanca Molins Sara Romero-Vázquez Pablo Fuentes-Prior Pablo Fuentes-Prior Alfredo Adan Andrew D. Dick Andrew D. Dick Andrew D. Dick |
| author_sort | Blanca Molins |
| collection | DOAJ |
| description | Age-related macular degeneration (AMD), a retinal degenerative disease, is the leading cause of central vision loss among the elderly population in developed countries and an increasing global burden. The major risk is aging, compounded by other environmental factors and association with genetic variants for risk of progression. Although the etiology of AMD is not yet clearly understood, several pathogenic pathways have been proposed, including dysfunction of the retinal pigment epithelium, inflammation, and oxidative stress. The identification of AMD susceptibility genes encoding complement factors and the presence of complement and other inflammatory mediators in drusen, the hallmark deposits of AMD, support the concept that local inflammation and immune-mediated processes play a key role in AMD pathogenesis that may be accelerated through systemic immune activation. In this regard, increased levels of circulating C-reactive protein (CRP) have been associated with higher risk of AMD. Besides being a risk marker for AMD, CRP may also play a role in the progression of the disease as it has been identified in drusen, and we have recently found that its monomeric form (mCRP) induces blood retinal barrier disruption in vitro. In this review, we will address recent evidence that links CRP and AMD pathogenesis, which may open new therapeutic opportunities to prevent the progression of AMD. |
| first_indexed | 2024-04-13T11:30:54Z |
| format | Article |
| id | doaj.art-712dcde6f6214ff49c0266a7d97bc26a |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-13T11:30:54Z |
| publishDate | 2018-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-712dcde6f6214ff49c0266a7d97bc26a2022-12-22T02:48:35ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-04-01910.3389/fimmu.2018.00808341528C-Reactive Protein as a Therapeutic Target in Age-Related Macular DegenerationBlanca Molins0Sara Romero-Vázquez1Pablo Fuentes-Prior2Pablo Fuentes-Prior3Alfredo Adan4Andrew D. Dick5Andrew D. Dick6Andrew D. Dick7Institut d’Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Barcelona, SpainMolecular Bases of Disease, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, SpainUniversitat Autònoma de Barcelona, Bellaterra, SpainInstitut d’Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Barcelona, SpainAcademic Unit of Ophthalmology, School of Clinical Sciences, University of Bristol, Bristol, United KingdomAcademic Unit of Ophthalmology, School of Cellular and Molecular Medicine, University of Bristol, Bristol, United KingdomNational Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital, University College London Institute of Ophthalmology, London, United KingdomAge-related macular degeneration (AMD), a retinal degenerative disease, is the leading cause of central vision loss among the elderly population in developed countries and an increasing global burden. The major risk is aging, compounded by other environmental factors and association with genetic variants for risk of progression. Although the etiology of AMD is not yet clearly understood, several pathogenic pathways have been proposed, including dysfunction of the retinal pigment epithelium, inflammation, and oxidative stress. The identification of AMD susceptibility genes encoding complement factors and the presence of complement and other inflammatory mediators in drusen, the hallmark deposits of AMD, support the concept that local inflammation and immune-mediated processes play a key role in AMD pathogenesis that may be accelerated through systemic immune activation. In this regard, increased levels of circulating C-reactive protein (CRP) have been associated with higher risk of AMD. Besides being a risk marker for AMD, CRP may also play a role in the progression of the disease as it has been identified in drusen, and we have recently found that its monomeric form (mCRP) induces blood retinal barrier disruption in vitro. In this review, we will address recent evidence that links CRP and AMD pathogenesis, which may open new therapeutic opportunities to prevent the progression of AMD.http://journal.frontiersin.org/article/10.3389/fimmu.2018.00808/fullC-reactive proteinmacular degenerationaginginflammationretina |
| spellingShingle | Blanca Molins Sara Romero-Vázquez Pablo Fuentes-Prior Pablo Fuentes-Prior Alfredo Adan Andrew D. Dick Andrew D. Dick Andrew D. Dick C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration Frontiers in Immunology C-reactive protein macular degeneration aging inflammation retina |
| title | C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration |
| title_full | C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration |
| title_fullStr | C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration |
| title_full_unstemmed | C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration |
| title_short | C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration |
| title_sort | c reactive protein as a therapeutic target in age related macular degeneration |
| topic | C-reactive protein macular degeneration aging inflammation retina |
| url | http://journal.frontiersin.org/article/10.3389/fimmu.2018.00808/full |
| work_keys_str_mv | AT blancamolins creactiveproteinasatherapeutictargetinagerelatedmaculardegeneration AT sararomerovazquez creactiveproteinasatherapeutictargetinagerelatedmaculardegeneration AT pablofuentesprior creactiveproteinasatherapeutictargetinagerelatedmaculardegeneration AT pablofuentesprior creactiveproteinasatherapeutictargetinagerelatedmaculardegeneration AT alfredoadan creactiveproteinasatherapeutictargetinagerelatedmaculardegeneration AT andrewddick creactiveproteinasatherapeutictargetinagerelatedmaculardegeneration AT andrewddick creactiveproteinasatherapeutictargetinagerelatedmaculardegeneration AT andrewddick creactiveproteinasatherapeutictargetinagerelatedmaculardegeneration |